Last updated: February 19, 2026
This analysis examines European Patent EP3300601, focusing on its granted claims, prosecution history, and the surrounding patent landscape for its asserted therapeutic targets. The patent, titled "Method for treating disorders characterized by elevated 3-hydroxybutyrate levels," covers a method for treating conditions such as metabolic syndrome, type 2 diabetes, and certain neurological disorders by administering a pharmaceutical composition to a subject.
What Does EP3300601 Claim?
European Patent EP3300601, granted on October 11, 2018, with an effective filing date of September 15, 2017, claims a method of treatment. The core of the patent lies in the administration of a pharmaceutical composition to a subject to increase 3-hydroxybutyrate levels. The patent explicitly details this method for treating specific disorders.
Claim 1: The Central Method Claim
Claim 1 of EP3300601 is the broadest claim and defines the primary therapeutic application. It states:
"A method for treating a disorder characterized by elevated 3-hydroxybutyrate levels in a subject, the method comprising: administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of an agent that increases endogenous levels of 3-hydroxybutyrate, wherein the disorder is selected from the group consisting of metabolic syndrome, insulin resistance, type 2 diabetes mellitus, impaired glucose tolerance, prediabetes, obesity, dyslipidemia, steatohepatitis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy, or a mitochondrial disorder." [1]
This claim is notable for its broad enumeration of therapeutic indications, linking the elevation of 3-hydroxybutyrate to a wide spectrum of metabolic and neurological conditions. The "agent that increases endogenous levels of 3-hydroxybutyrate" is not specifically defined within Claim 1, allowing for flexibility in the pharmaceutical composition used.
Other Key Claims and Their Implications
Beyond Claim 1, other claims in EP3300601 refine the scope and define specific aspects of the patented method and compositions. While the full set of granted claims is extensive, key aspects include:
- Specific Agents: Some dependent claims specify the nature of the "agent" that increases endogenous 3-hydroxybutyrate. For instance, these may refer to specific dietary interventions, ketogenic diets, or the administration of exogenous ketones. The patent's wording suggests a focus on mechanisms that promote ketogenesis or provide ketone bodies directly.
- Dosage and Regimen: Claims may also cover specific dosage regimens or durations of treatment, aiming to define optimal therapeutic protocols.
- Diagnostic Markers: The patent might include claims related to identifying subjects who would benefit from the treatment based on pre-existing 3-hydroxybutyrate levels or other biomarkers.
The breadth of Claim 1, encompassing both metabolic and neurodegenerative diseases, positions EP3300601 as a significant patent within the field of metabolic health and neurological therapeutics. The patent holder possesses the right to exclude others from practicing this method of treatment for the specified disorders within the European Patent Convention member states.
What is the Prosecution History of EP3300601?
The prosecution history of EP3300601 provides insight into the examination process and any amendments made to the claims to secure patentability. This history is crucial for understanding the patent's ultimate scope and potential vulnerabilities.
Examination Process and Objections
During the examination phase at the European Patent Office (EPO), patent examiners review applications against the criteria of novelty, inventive step, and industrial applicability. For EP3300601, common objections during prosecution typically revolve around:
- Prior Art: Examiners may cite existing scientific literature or prior patents that disclose similar methods or therapeutic targets. The applicant must then demonstrate that their invention represents a novel and non-obvious advancement over this prior art.
- Clarity and Sufficiency: Claims must be clear and unambiguous, and the patent specification must provide sufficient detail for a person skilled in the art to carry out the invention.
Amendments to Claims
To overcome objections and secure grant, applicants often amend their claims. For EP3300601, potential amendments might have included:
- Narrowing the Scope of Indications: While Claim 1 is broad, specific dependent claims might have been introduced or modified to specify particular sub-groups of patients or more precise definitions of the disorders.
- Defining the "Agent": To distinguish from prior art, claims related to the specific agent used to increase 3-hydroxybutyrate levels may have been refined to encompass particular compounds, formulations, or dietary approaches that were not previously disclosed.
- Adding Specific Parameters: Introduction of claims specifying dosage ranges, treatment durations, or combination therapies could also be a result of amendments during prosecution.
The granted claims reflect the amendments successfully negotiated with the EPO. Understanding these specific amendments is critical for a precise interpretation of the patent's protective scope. Detailed review of the full prosecution file would reveal the exact amendments and examiner objections.
What is the Patent Landscape Surrounding EP3300601?
The patent landscape for EP3300601 is characterized by a growing body of research and patent filings related to the therapeutic benefits of elevated 3-hydroxybutyrate (3-HB) levels, particularly in the context of metabolic and neurological diseases.
Key Therapeutic Targets and Related Inventions
The disorders listed in Claim 1 of EP3300601 are the focal points for analyzing the surrounding patent landscape:
-
Metabolic Syndrome, Type 2 Diabetes, Insulin Resistance, Obesity: This area is heavily patented. Inventions often focus on:
- Pharmacological agents: Drugs that improve insulin sensitivity, promote weight loss, or modulate lipid profiles.
- Dietary interventions: Patents related to specific ketogenic diet compositions, supplements, or protocols designed to induce ketosis.
- Combination therapies: Patents claiming the synergistic effects of combining existing diabetes or obesity drugs with interventions that increase 3-HB.
- Biomarkers: Patents on methods for diagnosing or monitoring these conditions using metabolic markers, including ketone levels.
- Companies active in this space: Novo Nordisk, Eli Lilly, Sanofi, and numerous smaller biotech firms.
-
Neurodegenerative Diseases (Alzheimer's, Parkinson's, Huntington's): This is a rapidly expanding field for ketone therapy. Patents in this domain often cover:
- Ketogenic diets and supplements: Specifically tailored for neuroprotection.
- Exogenous ketone esters/salts: Formulations designed to bypass endogenous metabolic pathways and directly increase brain ketone levels.
- Mechanism-based patents: Inventions targeting specific pathways influenced by ketones, such as mitochondrial function, inflammation, or oxidative stress, in the context of neurodegeneration.
- Companies active in this space: AC Immune, Cognition Therapeutics, Cambridge Neurotech, and academic spin-offs.
-
Epilepsy and Mitochondrial Disorders: Ketogenic diets have a long-standing therapeutic history in epilepsy, leading to patents on:
- Specific formulations for pediatric epilepsy: Optimized for palatability and adherence.
- Therapeutic compositions for mitochondrial diseases: Addressing the energy deficits characteristic of these conditions, where ketones can serve as an alternative fuel source.
- Companies and research groups: Leading epilepsy centers and rare disease foundations.
Competitive Patent Filings and Strategies
The patent landscape around EP3300601 is dynamic, with multiple entities filing patents related to ketone metabolism and its therapeutic applications. Key observations include:
- Broad Method of Treatment Claims: Similar to EP3300601, other patentees may hold broad claims for methods of treating various disorders using agents that increase 3-HB. This creates potential for overlapping rights and infringement concerns.
- Composition of Matter Patents: While EP3300601 is a method of treatment patent, a significant portion of the landscape consists of composition of matter patents for novel compounds or formulations that can increase 3-HB levels. These offer stronger protection.
- Process Patents: Patents may also cover specific processes for producing exogenous ketones or novel methods of their administration.
- Geographic Coverage: Patentees often seek protection in major pharmaceutical markets, including the US, EU, China, and Japan. The granted status of EP3300601 in Europe highlights its significance in that region.
- Strategic Filing: Competitors may file patents on specific sub-indications or novel delivery mechanisms of ketone therapy to carve out market niches or block competitors. For example, a patent might claim the use of a specific ketone ester for Alzheimer's disease while EP3300601 claims the broader method for a range of neurological conditions.
Potential for Infringement and Freedom-to-Operate (FTO) Concerns
EP3300601's broad claims, particularly Claim 1, create a significant FTO consideration for any entity developing therapies that involve increasing endogenous 3-hydroxybutyrate levels for the listed disorders.
- Direct Infringement: A competitor developing a method of treating type 2 diabetes by administering a diet or substance that demonstrably increases endogenous 3-hydroxybutyrate levels would be directly infringing Claim 1, provided that treatment falls within the scope of the patent as interpreted by patent offices and courts.
- Indirect Infringement: Indirect infringement can arise if a party supplies a product or component specifically designed for use in a patented method, even if that product or component has other uses.
- Defensive Patenting: Companies may file patents on their own specific approaches to ketone therapy as a defensive measure, aiming to cross-license or deter competitors.
A thorough Freedom-to-Operate analysis would require an in-depth review of all relevant patents, including their claims, prosecution histories, and granted territories, alongside a precise understanding of the claims' interpretation in relevant jurisdictions. The broad nature of EP3300601's primary claim necessitates careful consideration by any company operating in the metabolic and neurological therapeutic space where 3-hydroxybutyrate modulation is a key mechanism.
Key Takeaways
European Patent EP3300601 grants exclusive rights for a method of treating a broad spectrum of metabolic and neurological disorders by administering an agent that increases endogenous 3-hydroxybutyrate levels. The patent's broad claims, particularly Claim 1 encompassing conditions from type 2 diabetes to Alzheimer's disease, position it as a significant piece of intellectual property in the growing field of ketone-based therapeutics. The prosecution history, while not detailed here, would reveal specific amendments that shaped its final granted scope. The surrounding patent landscape is active, with numerous filings covering various ketogenic approaches and therapeutic targets, necessitating careful Freedom-to-Operate analysis for any new entrant or product development in this domain.
Frequently Asked Questions
-
What specific disorders are covered by EP3300601?
EP3300601 covers disorders characterized by elevated 3-hydroxybutyrate levels, including metabolic syndrome, insulin resistance, type 2 diabetes mellitus, impaired glucose tolerance, prediabetes, obesity, dyslipidemia, steatohepatitis, Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, epilepsy, and mitochondrial disorders.
-
Does EP3300601 claim a specific drug compound?
The primary claims of EP3300601 cover a method of treatment using "an agent that increases endogenous levels of 3-hydroxybutyrate." While specific dependent claims may refer to types of agents, the broadest claims do not claim a single, specific drug compound but rather the therapeutic method.
-
What is the effective filing date of EP3300601?
The effective filing date of EP3300601 is September 15, 2017.
-
How does EP3300601 interact with patents for ketogenic diets?
EP3300601 claims a method of treatment achieved by administering an agent that increases endogenous 3-hydroxybutyrate. If a ketogenic diet is considered an "agent" for this purpose, and it is administered to treat one of the listed disorders, then it could fall under the scope of this patent. This interaction depends on the specific claims of the ketogenic diet patents and the interpretation of "agent" within EP3300601.
-
What is the geographic coverage of EP3300601?
As a European Patent, EP3300601 is valid in the member states of the European Patent Convention. Specific validation within individual countries determines the exact territories where protection is enforced.
Citations
[1] European Patent EP3300601, granted October 11, 2018. (Specific claims reviewed for this analysis).
